| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
PPAR-α/δ[1]
Anti-NASH agent 1 targets PPAR-α/δ (peroxisome proliferator-activated receptors alpha and delta). PPARs are nuclear receptors that regulate lipid metabolism, inflammation, and energy homeostasis. By activating PPAR-α/δ, the compound modulates metabolic pathways involved in fatty acid oxidation, lipid metabolism, and inflammatory responses. This mechanism underlies its potential therapeutic effects in NASH. |
|---|---|
| ln Vitro |
In cell-free biochemical systems, Anti-NASH agent 1 acts as a potent agonist of PPAR-α/δ. The compound's activation of these nuclear receptors can be assessed using cell-free reporter assays or binding assays with purified PPAR proteins. The compound shows low liver toxicity in in vitro systems.
|
| ln Vivo |
In cell-based assays, Anti-NASH agent 1 modulates PPAR-α/δ signaling, leading to changes in lipid metabolism and inflammatory responses. The compound's effects are evaluated in hepatocyte cell lines or other relevant cell models. By activating PPAR-α/δ, the compound reduces lipid accumulation and inflammation. The compound shows low liver toxicity in cellular models.
|
| Enzyme Assay |
The cell-free assay for PPAR activation involves measuring the binding of the compound to purified PPAR-α/δ proteins or using cell-free transcription assays. The compound is incubated with PPAR proteins and a labeled ligand or coactivator, and binding is measured using fluorescence polarization, scintillation proximity assay, or other detection methods. The EC50 for activation is determined from dose-response curves.
|
| Cell Assay |
Cell-based assays for Anti-NASH agent 1 involve culturing hepatocytes or other relevant cell lines and treating them with the compound at concentrations ranging from 0.01 to 100 μM. PPAR activation is assessed by measuring the expression of PPAR target genes by qRT-PCR. Lipid accumulation is assessed by Oil Red O staining or measuring triglyceride levels. Inflammatory cytokine production is measured by ELISA.
|
| Animal Protocol |
In animal models, Anti-NASH agent 1 (3-10 mg/kg; 4 weeks) improves hyperlipidemia, hepatic steatosis, and hepatic inflammation in methionine-choline deficiency (MCD)-induced NASH mouse models. The compound (3-30 mg/kg) decreases disease severity, reduces serum triglyceride, total cholesterol, LDL, AST, ALT, TNF-α, IL-6, and IL-8 levels, and increases serum HDL and liver GSH levels in NASH mouse models.
|
| ADME/Pharmacokinetics |
Anti-NASH agent 1 exhibits favorable pharmacokinetic properties. The compound is orally bioavailable and achieves therapeutic concentrations in tissues. In vivo studies have been conducted at doses of 3-10 mg/kg and 3-30 mg/kg. The compound shows low liver toxicity. Detailed pharmacokinetic parameters including plasma half-life, clearance, and volume of distribution have been reported in preclinical studies.
|
| Toxicity/Toxicokinetics |
Anti-NASH agent 1 shows low liver toxicity in preclinical studies. The compound demonstrates a favorable safety profile with potent liver protection effects. Standard toxicology studies in animal models have been conducted to determine the maximum tolerated dose and target organ toxicity. The compound's low hepatotoxicity makes it a promising candidate for NASH research.
|
| References | |
| Additional Infomation |
Anti-NASH agent 1 is a research compound being investigated for the treatment of non-alcoholic steatohepatitis (NASH). It is a derivative of Elafibranor and a potent PPAR-α/δ agonist. The compound shows low liver toxicity and demonstrates strong liver protection. It is not an approved pharmaceutical and has no clinical trial history. This product is intended for research use only.
|
| Molecular Formula |
C26H33NO4
|
|---|---|
| Molecular Weight |
423.544527769089
|
| Exact Mass |
423.24
|
| Elemental Analysis |
C, 73.73; H, 7.85; N, 3.31; O, 15.11
|
| CAS # |
2409685-41-0
|
| PubChem CID |
148083935
|
| Appearance |
Light yellow to yellow solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
31
|
| Complexity |
628
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C1C(C)=CC(/C=C/C(C2C=CC(=CC=2)NC)=O)=CC=1C)C(C)(C)C(=O)OC(C)(C)C
|
| InChi Key |
JMNQFYWMYKSSSA-NTEUORMPSA-N
|
| InChi Code |
InChI=1S/C26H33NO4/c1-17-15-19(9-14-22(28)20-10-12-21(27-8)13-11-20)16-18(2)23(17)30-26(6,7)24(29)31-25(3,4)5/h9-16,27H,1-8H3/b14-9+
|
| Chemical Name |
tert-butyl (E)-2-(2,6-dimethyl-4-(3-(4-(methylamino)phenyl)-3-oxoprop-1-en-1-yl)phenoxy)-2-methylpropanoate
|
| Synonyms |
Anti-NASH agent 1; Anti-NASH agent-1; Anti NASH agent 1; Anti-NASH-agent 1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~236.1 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (5.90 mM) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution; with ultrasonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3611 mL | 11.8053 mL | 23.6105 mL | |
| 5 mM | 0.4722 mL | 2.3611 mL | 4.7221 mL | |
| 10 mM | 0.2361 mL | 1.1805 mL | 2.3611 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
